Literature DB >> 19125742

CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions.

Juan C Tardío1.   

Abstract

Over the past few years, a growing number of cutaneous tumors expressing CD34 is being reported. The list contains benign and malignant neoplasms as well as reactive and hamartomatous lesions of diverse lineages of differentiation, including fibroblastic, myofibroblastic, fibrohistiocytic, vascular, neural, adipocytic, smooth muscle, hematopoietic, melanocytic and epithelial. The more frequent diagnostic difficulties are found in spindle cell proliferations, mainly in those of the fibrocytic lineage. In part, this is because of the fact that in this area are, aside to well-defined entities, histologically and clinically diverse, recently reported cutaneous CD34-reactive lesions, whose definitions, limits and relationships are not completely established. The CD34 expression plays a key role in the differential diagnosis of some tumors, such as dermatofibrosarcoma protuberans, epithelioid sarcoma or pleomorphic hyalinizing angiectatic tumor of soft parts, with important therapeutic consequences. In others, as in desmoplastic trichilemmoma, it can help to resolve diagnostic problems in concrete cases. Finally, in many of the CD34-positive lesions, the diagnosis with the hematoxylin and eosin stain is straightforward. However, in all of them, the knowledge of the immunohistochemical profile contributes to our understanding of the cutaneous pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125742     DOI: 10.1111/j.1600-0560.2008.01212.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  14 in total

1.  Trichilemmoma arising in the nasal vestibule: report of three cases with special emphasis on the differential diagnosis.

Authors:  Marisa Herráiz; Luz M Martín-Fragueiro; Juan C Tardío
Journal:  Head Neck Pathol       Date:  2012-06-06

2.  Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model.

Authors:  Aniket Sakharpe; Guy Lahat; Taher Gulamhusein; Ping Liu; Svetlana Bolshakov; Theresa Nguyen; Pingyu Zhang; Roman Belousov; Eric Young; Xianbiao Xie; Priya Rao; Jason L Hornick; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Oncologist       Date:  2011-02-28

3.  Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma.

Authors:  Urs Naber; Reinhard E Friedrich; Markus Glatzel; Victor Felix Mautner; Christian Hagel
Journal:  J Neurooncol       Date:  2010-09-07       Impact factor: 4.130

Review 4.  Dermatofibrosarcoma Protuberans in Children.

Authors:  Aseel Sleiwah; Thomas C Wright; Thomas Chapman; Adam Dangoor; Francesca Maggiani; Rachel Clancy
Journal:  Curr Treat Options Oncol       Date:  2022-04-08

5.  Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Authors:  Banafsheh Nazari; Lisa M Rice; Giuseppina Stifano; Alexander M S Barron; Yu Mei Wang; Tess Korndorf; Jungeun Lee; Jag Bhawan; Robert Lafyatis; Jeffrey L Browning
Journal:  Am J Pathol       Date:  2016-08-23       Impact factor: 4.307

6.  Dermatofibrosarcoma protuberans in a 10-year-old child.

Authors:  Uwe Wollina
Journal:  J Dermatol Case Rep       Date:  2013-12-30

Review 7.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

8.  What makes cancer stem cell markers different?

Authors:  Uwe Karsten; Steffen Goletz
Journal:  Springerplus       Date:  2013-07-04

9.  A quiz from Manaus, Brazil.

Authors:  Mario F Ribeiro de Miranda; Antonio P Mendes Schettini; Laís Cruz Lobato; Renato C da Silva; Patricia Motta de Morais; Maraya de Jesus Semblano Bittencourt
Journal:  Dermatol Pract Concept       Date:  2015-10-31

10.  Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.

Authors:  Julia Herzog; Sandra M Ehrlich; Lisa Pfitzer; Johanna Liebl; Thomas Fröhlich; Georg J Arnold; Wolfgang Mikulits; Christine Haider; Angelika M Vollmar; Stefan Zahler
Journal:  Oncotarget       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.